BIOSANTE PHARMACEUTICALS INC Form 424B3 May 08, 2013

Use these links to rapidly review the document <u>TABLE OF CONTENTS</u> <u>INDEX TO BIOSANTE'S FINANCIAL STATEMENTS</u> <u>INDEX TO ANI'S FINANCIAL STATEMENTS</u> TABLE OF CONTENTS

Table of Contents

Filed Pursuant to Rule 424(b)(3) Registration No. 333-188174

PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT

To our Stockholders:

On April 12, 2013, BioSante Pharmaceuticals, Inc. (BioSante) and ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc. (ANI), entered into an amended and restated merger agreement pursuant to which ANI Merger Sub, Inc., a wholly owned subsidiary of BioSante, will merge with and into ANI with ANI continuing as the surviving company and becoming a wholly owned subsidiary of BioSante. The boards of directors of BioSante and ANI have approved unanimously the merger agreement and the merger and believe that the combination of BioSante and ANI will create more value than either company could achieve individually. The combined company that will result from the merger will be a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing branded and generic prescription pharmaceuticals.

Pursuant to the terms of the merger agreement, upon completion of the merger, ANI stockholders will have the right to receive, for each share of ANI capital stock they hold, that number of shares of BioSante common stock, if any, as determined pursuant to the exchange ratios described in the merger agreement and the provisions of ANI's certificate of incorporation. Following completion of the merger, ANI stockholders will own 57 percent of the outstanding shares of common stock of the combined company, and BioSante stockholders will own 43 percent of the outstanding shares of common stock of the combined company.

BioSante common stock is listed on The NASDAQ Global Market and trades under the symbol "BPAX". On May 7, 2013, the latest practicable date before the printing of this joint proxy statement/prospectus, the closing sale price of BioSante common stock was \$1.17 per share. ANI is a privately held specialty pharmaceutical company.

This joint proxy statement/prospectus provides you with detailed information about the special meeting of stockholders of BioSante to consider the issuance of shares of BioSante common stock in the merger and other matters and the special meeting of stockholders of ANI to consider the merger and related business. **Your vote is very important.** Whether or not you plan to attend your respective company's meeting of stockholders, please submit your proxy as soon as possible to make sure that your shares are represented at the applicable meeting. In addition to being a proxy statement for both BioSante and ANI, this document is also a prospectus to be used by BioSante when issuing BioSante common stock to ANI stockholders in connection with the merger. BioSante and ANI encourage you to read the entire document carefully. **Please pay particular attention to the section entitled ''Risk Factors'' beginning on page 38 for a discussion of the risks related to the merger, the combined company following completion of the merger, and the business and operations of each of BioSante and ANI.**

BioSante and ANI are excited about the opportunities that the proposed merger brings to both BioSante and ANI stockholders and thank you for your consideration and continued support.

Stephen M. Simes Vice Chairman, President and Chief Executive Officer BioSante Pharmaceuticals, Inc.

Arthur S. Przybyl President and Chief Executive Officer ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the BioSante common stock to be issued pursuant to the merger or determined if the information in this joint proxy statement/prospectus is accurate or adequate. Any representation to the contrary is a criminal offense.

This joint proxy statement/prospectus is dated May 8, 2013 and is first being mailed or otherwise delivered to stockholders of BioSante and ANI on or about May 10, 2013.

Table of Contents

REFERENCES TO ADDITIONAL INFORMATION

This joint proxy statement/prospectus forms a part of a registration statement on Form S-4 filed by BioSante Pharmaceuticals, Inc. with the Securities and Exchange Commission (SEC). It constitutes a prospectus of BioSante under Section 5 of the Securities Act of 1933, as amended (the Securities Act), and the rules and regulations thereunder, with respect to the shares of BioSante common stock to be issued to holders of capital stock of ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc. in the merger. In addition, it constitutes a proxy statement under Section 14(a) of the Securities Exchange Act of 1934, as amended (the Exchange Act), and the rules and regulations thereunder, and a notice of meeting with respect to the BioSante special meeting of stockholders. It also constitutes a proxy statement of ANI and a notice of meeting with respect to the ANI special meeting of stockholders.

BioSante has supplied all information contained in this joint proxy statement/prospectus relating to BioSante and ANI has supplied all information contained in this joint proxy statement/prospectus relating to ANI.

If you would like to request documents from BioSante or ANI, please send a request by telephone or email to either BioSante or ANI at the following address:

BioSante Pharmaceuticals, Inc. 111 Barclay Boulevard Lincolnshire, Illinois 60069 Attention: Investor Relations Tel: (847) 478-0500 ext. 120 Email: info@biosantepharma.com ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc. 210 Main Street West Baudette, Minnesota 56623 Attention: Investor Relations Tel: (218) 634-3500 Email: arthur.przybyl@anipharmaceuticals.com

If you would like to request documents, please do so by May 29, 2013 in order to receive them before the special meetings. See "Where You Can Find More Information" beginning on page 323.

Table of Contents

BioSante Pharmaceuticals, Inc.

NOTICE OF SPECIAL MEETING OF STOCKHOLDERS IN LIEU OF ANNUAL MEETING OF STOCKHOLDERS To Be Held On June 19, 2013

Dear BioSante Stockholder:

A special meeting of the stockholders of BioSante Pharmaceuticals, Inc. will be held on June 19, 2013 at 8:00 a.m., local time, at BioSante's corporate office located at 111 Barclay Boulevard, Lincolnshire, Illinois 60069, for the following purposes:

1.

To elect seven persons to serve as directors until BioSante's next annual meeting of stockholders or until their respective successors are elected and qualified.

2.

To consider and vote upon a proposal to approve the issuance of BioSante common stock, par value \$0.0001 per share, in the merger contemplated by the amended and restated agreement and plan of merger, dated as of April 12, 2013, by and among BioSante, ANI Merger Sub, Inc., a wholly owned subsidiary of BioSante, and ANI, a copy of which is attached as Annex A to the joint proxy statement/prospectus accompanying this notice.

3.

To consider and vote upon a proposal to ratify the selection of Deloitte & Touche LLP as BioSante's independent registered public accounting firm for the year ending December 31, 2013.

4.

To consider and vote upon a proposal to approve, on an advisory (non-binding) basis, the compensation payable to certain executive officers of BioSante under existing arrangements in connection with the merger.

5.

To consider and vote upon a proposal to approve an adjournment of the BioSante special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of BioSante Proposal No. 2.

Stockholders also will consider and act on any other matters that may properly come before the special meeting or any adjournment or postponement thereof, including any procedural matters incident to the conduct of the special meeting.

The special meeting will be in lieu of an annual meeting of stockholders of BioSante and thus the items of business to be considered by BioSante stockholders at the special meeting include the election of directors and the ratification of the selection of BioSante's independent registered public accounting firm for the year ending December 31, 2013. BioSante stockholders should understand, however, that if the merger with ANI is completed, the effect of the approval of BioSante Proposals No. 1 and 3 will be limited since the composition of the BioSante board of directors will be changed upon completion of the merger and it is likely that the combined company may switch auditors immediately or shortly after completion of the merger.

The board of directors of BioSante has fixed May 8, 2013 as the record date for the determination of BioSante stockholders entitled to notice of, and to vote at, the BioSante special meeting or any adjournments or postponements of the BioSante special meeting. Only holders of record of BioSante common stock and BioSante class C special stock at the close of business on the BioSante record date are entitled to notice of, and to vote at, the BioSante special meeting. At the close of business on the record date, BioSante had 24,422,240 shares of common stock and 65,211 shares of BioSante class C special stock outstanding and entitled to vote.

Table of Contents

Your vote is important. The affirmative vote of holders of a plurality of the BioSante common stock and BioSante class C special stock, voting together as a single class, present at the BioSante special meeting in person or by proxy and entitled to vote on the proposal, is required for approval of BioSante Proposal No. 1. The affirmative vote of the holders of a majority of the BioSante common stock and class C special stock, voting together as a single class, present at the BioSante special meeting in person or by proxy and entitled to vote on the proposal, is required for approval of BioSante Proposal Soc. 2, 3, 4 and 5. The approval of BioSante Proposal No. 2, 2 is not conditioned upon the approval of BioSante Proposal No. 2, 3, 4 or 5, and the approval of BioSante Proposals No. 1, 3, 4 or 5 is not conditioned upon the approval of BioSante Proposal No. 2.

Even if you plan to attend the BioSante special meeting in person, BioSante requests that you complete, sign and return the enclosed proxy card and thus ensure that your shares will be represented at the BioSante special meeting if you are unable to attend. If you sign, date and mail your proxy card without indicating how you wish to vote, your proxy will be counted as a vote in favor of BioSante Proposals No. 1 through 5. If you fail to return your proxy card, the effect will be that your shares will not be counted for purposes of determining whether a quorum is present at the BioSante special meeting. If you do attend the BioSante special meeting and wish to vote in person, you may withdraw your proxy and vote in person.

The BioSante board of directors has determined that the issuance of shares of BioSante common stock in the merger is advisable and in the best interests of BioSante and its stockholders. The BioSante board of directors unanimously has approved the issuance of shares of BioSante common stock in the merger, and recommends that BioSante stockholders vote "FOR" the issuance of shares of BioSante common stock in the merger, "FOR" all seven of the nominees for director in BioSante Proposal No. 1 and "FOR" all other proposals.

By Order of the Board of Directors,

Phillip B. Donenberg Senior Vice President of Finance, Chief Financial Officer and Secretary

May 8, 2013 Lincolnshire, Illinois IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR BIOSANTE'S SPECIAL MEETING TO BE HELD ON JUNE 19, 2013

The accompanying joint proxy statement/prospectus is available at www.proxyvote.com/BioSante.

ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc.

NOTICE OF SPECIAL MEETING OF STOCKHOLDERS To Be Held On June 19, 2013

Dear ANI Stockholder:

A special meeting of the stockholders of ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc. will be held on June 19, 2013 at 9:00 a.m., local time, at the offices of MVP Capital Partners located at 259 N. Radnor-Chester Road, Suite 130, Radnor, Pennsylvania 19087, for the following purposes:

1.

To consider and vote upon a proposal to adopt the amended and restated agreement and plan of merger, dated as of April 12, 2013, by and among BioSante, ANI Merger Sub, Inc., a wholly owned subsidiary of BioSante, and ANI, a copy of which is attached as Annex A to the joint proxy statement/prospectus accompanying this notice, and the transactions contemplated thereby, including the merger.

2.

To consider and vote upon a proposal to approve an adjournment of the ANI special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of ANI Proposal No. 1.

Stockholders also will consider and act on any other matters that may properly come before the special meeting or any adjournment or postponement thereof, including any procedural matters incident to the conduct of the special meeting.

The board of directors of ANI has fixed May 8, 2013 as the record date for the determination of ANI stockholders entitled to notice of, and to vote at, the ANI special meeting or any adjournments or postponements of the ANI special meeting. Only holders of record of ANI capital stock at the close of business on the ANI record date are entitled to notice of, and to vote at, the ANI special meeting. At the close of business on the record date, ANI had 2,375,312 shares of series D convertible preferred stock, 34,810 shares of series C convertible preferred stock, 78,491 shares of series B convertible preferred stock, 102,774 shares of series A convertible preferred stock and 23,613 shares of common stock outstanding and entitled to vote.

Your vote is important. The affirmative vote of holders of a majority of the shares of ANI common stock, calculated on an as-converted basis and voting together as a single class, and 65 percent of the shares of ANI series D convertible preferred stock having voting power outstanding on the record date for the ANI special meeting is required for approval of ANI Proposal No. 1. The affirmative vote of holders of a majority of ANI common stock, calculated on an as-converted basis, present in person or represented by proxy at the ANI special meeting, is required for approval of ANI Proposal No. 2.

Even if you plan to attend the ANI special meeting in person, ANI requests that you complete, sign and return the enclosed proxy card and thus ensure that your shares will be represented at the ANI special meeting if you are unable to attend. If you sign, date and mail your proxy card without indicating how you wish to vote, your proxy will be counted as a vote in favor of ANI Proposals No. 1 and 2. If you fail to return your proxy card, the effect will be that your shares will not be counted for purposes of determining whether a quorum is present at the ANI special meeting and will count as a vote against ANI Proposal No. 1. If you do attend the ANI special meeting and wish to vote in person, you may withdraw your proxy and vote in person.

Table of Contents

The ANI board of directors has determined that the merger agreement and the transactions contemplated by it, including the merger, are advisable and in the best interests of ANI and its stockholders. The ANI board of directors has unanimously approved and adopted the merger agreement and the transactions contemplated by it, including the merger, and recommends that ANI stockholders vote "FOR" the adoption of the merger agreement and the transactions contemplated thereby, including the merger, and "FOR" the adjournment of the ANI special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of ANI Proposal No. 1.

By Order of the Board of Directors,

Charlotte C. Arnold Vice President and Chief Financial Officer

Baudette, Minnesota May 8, 2013

TABLE OF CONTENTS

	Page
QUESTIONS AND ANSWERS ABOUT THE MERGER	<u>1</u>
QUESTIONS AND ANSWERS FOR BIOSANTE STOCKHOLDERS ABOUT THE BIOSANTE SPECIAL MEETING	
	<u>6</u>
QUESTIONS AND ANSWERS FOR ANI STOCKHOLDERS ABOUT THE ANI SPECIAL MEETING	-
	<u>12</u>
SUMMARY	12
SUMMART	16
	<u>16</u>
<u>The Companies</u>	<u>16</u>
Summary of the Merger	<u>17</u>
Reasons for the Merger	<u>17</u>
Opinion of Oppenheimer & Co. Inc.	<u>18</u>
<u>Risk Factors</u>	<u>19</u>
Merger Consideration	19
Treatment of ANI Stock Options and Warrants	$\overline{20}$
Treatment of BioSante Stock Options and Warrants	20
Management of the Combined Company Following the Merger	20
	$\frac{21}{21}$
Interests of BioSante's Directors and Officers in the Merger	$\frac{21}{22}$
Interests of ANI's Directors and Officers in the Merger	22
Conditions to Completion of the Merger	<u>23</u>
No Solicitation	<u>24</u>
Termination of the Merger Agreement	<u>25</u>
Termination Fees and Expenses	$ \begin{array}{r} 17 \\ 17 \\ 18 \\ 19 \\ 20 \\ 20 \\ 20 \\ 20 \\ 21 \\ 21 \\ 22 \\ 23 \\ 24 \\ 25 \\ 26 \\ \end{array} $
Vote Required	<u>26</u>
Voting Agreements	$\overline{26}$
Material U.S. Federal Income Tax Consequences of the Merger	27
Regulatory Approvals	26 27 27 28 28 28 28 28 28 28 29
Anticipated Accounting Treatment	27
	20
<u>Appraisal Rights</u>	<u>28</u>
Comparison of Stockholder Rights	<u>28</u>
Contingent Value Rights	<u>28</u>
Differences Between Proposed Merger Transaction and Prior Merger Transaction	<u>29</u>
SELECTED HISTORICAL FINANCIAL INFORMATION AND UNAUDITED PRO FORMA CONDENSED COMBINED	
FINANCIAL INFORMATION AND DATA	<u>30</u>
Selected Historical Financial Data of BioSante	<u>30</u>
Selected Historical Financial Data of ANI	31
Summary Unaudited Pro Forma Condensed Combined Financial Data of BioSante and ANI	<u>31</u> <u>32</u>
COMPARATIVE HISTORICAL AND UNAUDITED PRO FORMA PER SHARE DATA	<u>. </u>
COM ARATIVE MISTORICAL AND OWNOFILD TROTORMATER SHARE DATA	24
MARKET PRICE AND DIVIDEND INFORMATION	<u>34</u>
MARKET PRICE AND DIVIDEND INFORMATION	
	<u>35</u> 35
BioSante	
ANI	<u>37</u>
<u>RISK FACTORS</u>	
	<u>38</u>
Risks Related to the Merger	38
Risks Related to the Combined Company if the Merger is Completed	44
Risks Related to BioSante	<u>49</u>
Risks Related to ANI	<u>12</u> 73
CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS	<u>15</u>
CAUTIONART STATEMENT CONCERNING FORWARD-LOUKING STATEMENTS	07
	<u>87</u>

	Page
THE SPECIAL MEETING OF BIOSANTE STOCKHOLDERS	<u>88</u>
General	<u>88</u>
Date, Time and Place	<u>88</u>
Purposes of the BioSante Special Meeting	<u>88</u>
Recommendations of the BioSante Board of Directors	88
Record Date and Voting Power	89
Voting and Revocation of Proxies	89
Quorum and Required Vote	90
Solicitation of Proxies	88 88 88 89 90 91 91 91 91
Delivery of Proxy Materials to Households Where Two or More Stockholders Reside	91
Other Matters	01
	<u>91</u>
MATTERS BEING SUBMITTED TO A VOTE OF BIOSANTE STOCKHOLDERS	02
	<u>92</u>
BioSante Proposal No. 1 Election of Directors	<u>92</u>
BioSante Proposal No. 2 The Issuance of Shares of BioSante Common Stock in the Merger	<u>93</u>
BioSante Proposal No. 3 Ratification of Selection of Independent Registered Public Accounting Firm	<u>94</u>
BioSante Proposal No. 4 Advisory Vote on Golden Parachute Compensation	92 93 94 96 97
BioSante Proposal No. 5 Approval of Possible Adjournment of the BioSante Special Meeting	<u>97</u>
THE SPECIAL MEETING OF ANI STOCKHOLDERS	
	<u>98</u>
General	<u>98</u>
Date. Time and Place	<u>98</u>
Purposes of the ANI Special Meeting	98
Recommendations of the ANI Board of Directors	98
Record Date and Voting Power	98
Voting and Revocation of Proxies	00
Ouorum and Required Vote	98 98 98 98 98 98 99 99
	<u>99</u> 100
Solicitation of Proxies	
Other Matters	<u>100</u>
MATTERS BEING SUBMITTED TO A VOTE OF ANI STOCKHOLDERS	101
	<u>101</u>
ANI Proposal No. 1 Adoption of Agreement and Plan of Merger and the Transactions Contemplated Thereby, Including the Merger	<u>101</u>
ANI Proposal No. 2 Approval of Possible Adjournment of the ANI Special Meeting	<u>102</u>
<u>THE MERGER</u>	
	<u>103</u>
General	<u>103</u>
Background of the Merger	<u>103</u>
BioSante Reasons for the Merger	<u>118</u>
ANI Reasons for the Merger	123
Opinion of Oppenheimer & Co. Inc.	125
Certain Financial Forecasts of ANI Used in Connection with the Merger	131
Interests of BioSante's Directors and Officers in the Merger	134
Interests of ANI's Directors and Officers in the Merger	138
Regulatory Approvals	$\frac{130}{140}$
NASDAQ Listing of BioSante Common Stock	$\frac{140}{140}$
Restrictions on Sales of BioSante Common Stock Received by ANI Stockholders in the Merger	
	$\frac{140}{141}$
Material U.S. Federal Income Tax Consequences of the Merger	$\frac{141}{141}$
Anticipated Accounting Treatment	$\frac{141}{142}$
Appraisal Rights	<u>142</u>
ii	

instinct of the Merger 16 impletion of the Merger 16 inspletion of the Merger 16 indering of the Merger 16 consideration and Adjustment 16 indering of Nat Stock Options and Warantis 16 conditions to Completion of the Merger 18 vocations to Completion of the Merger 151 conduct of Business Pending the Merger 152 continuits 152 fore Arreneuts 152 fermination fees and Expenses 152 fermination of Prior Merger Agreement 153 Munchinents 155 voluing Agreements 155 voluing Agreements 157 consk-Up Arreneuts 157 consk-Up Arreneuts 157 consk-Up Arreneuts 157 consk-Up Arreneuts 157 construct value Richts Arreneuts 157 continger Value Richts Arre		Page
Completion of the Merger 146 Merger Consideration and Adiustment 146 retreatment of ANI Stock Options and Warrants 147 Conditions to Completion of the Merger 148 So Solicitation 148 Meetings of Stockholders, Change in Board Recommendation 150 Overnants, Conduct of Business Pending the Merger 151 Other Aercements 152 Ermination Flees and Expenses 152 Fermination of Prior Merger Agreement 153 Vinendments 154 Fermination of Prior Merger Agreements 155 Vinendments 155 VOTING AND OTHER ANCILLARY AGREEMENTS 157 Solicitation of the Reger 158 Orthing Agreements 157 Solicitation of the Solica to Issue CVRs 159 Solicitation of Solante to Issue CVRs 159 Solante Coling Agreements 159 Sol	THE MERGER AGREEMENT	<u>146</u>
derger Consideration and Adjustment 145 Freatment of ANI Stock Options and Warrants 147 conditions to Completion of the Merger 148 Vacetinues of Stockholders: Change in Board Recommendation 150 Constrict Conduct of Business Pending the Merger 151 Date Agreements 152 Fermination 152 Fermination fees and Expenses 152 Fermination of Prior Merger Agreement 153 Agreements 154 Fermination of Prior Merger Agreement 155 Amendments 155 Anneadments 157 Stockhold Streements 157 Stockhold Streements 157 Stockhold Streements 157 Stockhold Streements 158 CONTING ENT VALUE RIGHTS 157 Conting Agreements 158 CONTINGENT VALUE RIGHTS 159 Conting Charles Agreements 159 Conting Agreements 159 Conting Charles Agreements 159 Contring Charl	Structure of the Merger	
Treatment of ANI Steck Options and Warrants147Conditions to Completion of the Merger148Solucitation148Meetings of Stockholders: Change in Board Recommendation150Overnants: Conduct of Business Pending the Merger151Dater Agreements152Ermination I fees and Expenses153Remination I fees and Expenses154Remination I fees and Expenses154Remination I fees and Expenses155Amendments155Amendments155Other Agreement155Solucitation AND OTHER ANCILLARY AGREEMENTS157Solucitation Agreements157Solucitation Agreements157Solucitation Agreements157Solucitation Agreements159Contingert Value Richts Agreement159Solucitation Of BioSante Oligon Agreement159Solucitation Of BioSante Oligon Agreement159Solucitation Of BioSante Oligon Agreement159Solucitation Of BioSante Oligon Of TAX CONSEOUENCES OF THE MERGER161Solucitation Of BioSante Stemale Sexual Health. Menopause. Contraception and Male Hypogonadism Productis164Solucitation Of BioSante's Female Sexual Health. Menopause. Contraception and Male Hypogonadism Productis161Solucitation150151Solucitation Of BioSante's Female Sexual Health. Menopause. Contraception and Male Hypogonadism Productis164Solucitation151151Solucitation151Solucitation152Solucitation <t< td=""><td>Completion of the Merger</td><td></td></t<>	Completion of the Merger	
Conditions to Completion of the Merger 148 No Solicitation 148 No Solicitation 148 No Solicitation 148 Vocantatic, Conduct of Business Pending the Merger 151 Det Agreements 152 Commination Frees and Expenses 152 Remination frees and Expenses 153 Reresentations and Warranties 154 Mandation frees and Expenses 155 VOTING AND OTHER ANCILLARY AGREEMENTS 157 Noting Agreements 157 Noting Agreements 157 Cock-Up Agreements 157 Cock-Up Agreements 157 Conting Agreements 157 Cock-Up Agreements 157 Conting Agreements 157 Conting Agreements 157 Conting Agreements 159 Conting of the CVRs 159 Conting of the CVRs 159 Solicition of BioSante to Issue CVRs 159 Solicition of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products 161 Solicition of BioSante's Female Sexual Health, Menopause, Contraception and Male Hy	Merger Consideration and Adjustment	<u>146</u>
So Solicitation148Meetings of Stockholders; Change in Board Recommendation150Overnants; Conduct of Business Pending the Merger151Uher Agreements152fermination152fermination of Pior Merger Agreement153kenresentations and Warranties154remination of Pior Merger Agreement155Vancentations and Warranties156vorting Agreements157StoSante Voting Agreements157NI Voting Agreements157StoSante Voting Agreements157StoSante Voting Agreements158Contingent VALUE RIGHTS157Joscante Voting Agreements159Jointingent Value Rights Agreement159Jointingent Value Rights Agreement159Jointingent Value Rights Agreement159Jointereot of Biosante to Issue CVRs169Jistereiton of BioSante Votis Serventa161Streation of BioSante Sexual Health, Menopause, Contraception and Male Hypogonadism Products166Sales and Marketing111Jaundardutring111Jaundardutring111Jaundardutring112Jaundardutring112Jaundardutring123Jaundardutring123Jaundardutring123Jaundardutring123Jaundardutring123Jaundardutring123Jaundardutring123Jaundardutring123Jaundardutring123Jaundardutring123<	Treatment of ANI Stock Options and Warrants	<u>147</u>
Meetines of Stockholders: Change in Board Recommendation150Covenants: Conduct of Business Pending the Merger151Iber Agreements152Termination Fees and Expenses153Representations and Warranties153Representations and Warranties154Iermination of Prior Merger Agreement155Wonendments156VOTING AND OTHER ANCILLARY AGREEMENTS157XIN Voting Agreements157SioSante Voting Agreements157Contingent Value Rights Agreements159Contingent Value Rights Agreement159Contingent Value Rights Agreement159Contingent Value Rights Agreement159Scarte to BioSante to Issue CVRs160Material Terms of the CVRs160Material Terms of the CVRs160Material Terms of the CVRs161Scarte to BioSante Stermal Secural Health. Menopause. Contraception and Male Hypogonadism Products166Sales and Marketing121Agenetics150Stortes and Product Development121Yamufacturing121Zoverinental Regulation122Storportes158Protecting158Protecting159Stortes and Proprietary Rights150Storportes154Protecting154Storportes155Protecting159Storportes159Storportes159Storportes159Storportes150Sto	Conditions to Completion of the Merger	<u>148</u>
Sovemats: Conduct of Business Pending the Merger 151 Dher Agreements 152 cermination 152 fermination fees and Expenses 153 genestication of Prior Merger Agreement 153 termination of Prior Merger Agreement 155 Amendments 156 OTTING AND OTHER ANCILLARY AGREEMENTS 157 Solosante Voting Agreements 157 Solosante Voting Agreements 157 Solosante Voting Agreements 157 Solosante Voting Agreements 158 Contingent Value Rights Agreement 159 Solosante Value Rights Agreement 159 Solosante Ox Value Rights Agreement 159 Solosante Ox Value Rights Agreement 159 Solosante Ox Solosante O Issue CVRs 159 Material Terms of the CVRs 159 Solosante O Issue CVRs 160 Material Terms of the CVRs 161 Solosante O Issue CVRs 164 Solosante O Issue CVRs 164 Solosante O Issue CVRs 164 Solosante O Issue CVRs 164 </td <td>No Solicitation</td> <td><u>148</u></td>	No Solicitation	<u>148</u>
Duber Agreements152Cermination153Ermination Fees and Expenses154Remination Fees and Expenses154Vernination of Prior Merger Agreement155Muendments156VOTING AND OTHER ANCILLARY AGREEMENTS157Sindsante Voting Agreements157Sindsante Voting Agreements157Cock-Up Agreements157Conting Agreements157Conting Agreements157Conting Agreements157Conting Agreements158Conting Agreements158Conting Agreements159Conting Markense159Conting Markense159Conting Markense159Conting Markense159Conting Markense161Steretion of BioSante to Issue CVRs161Conting Agreement159Conting Markense161Conting Markense171Markense171Markense171Markense172Conting Markense172Conting Mar	Meetings of Stockholders; Change in Board Recommendation	<u>150</u>
Ermination152Ermination Fees and Expenses153kerresentations and Warrantics154Ermination of Prior Merger Agreement155Amendments156VOTING AND OTHER ANCILLARY AGREEMENTS157an Voting Agreements157SioSante Voting Agreements157SioSante Voting Agreements157SioSante Voting Agreements158CONTINGENT VALUE RIGHTS159Contingent Value Rights Agreement159Contingent Value Rights Agreement159Contingent Value Rights Agreement159SioSante Voting Agreement159Contingent Value Rights Agreement159Material Terms of the CVRs150Vaterial Terms of the CVRs160MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE MERGER161Contrigent Value Rights Agreement161Stes and Marketing121Agreenting Parate Sexual Health, Menopause, Contraception and Male Hypogonadism Products166Stes and Marketing121Agreent, Rights121Agreent, Rights121Stes and Marketing121Competition122Stes and Product Development122Sterest and Product Development122Sterest and Product Development123Suppetities124Sterest and Product Development122Sterest and Proceedings128Suppetities129Startens, Licenses and Progrietary Rights129Suppetities<	Covenants; Conduct of Business Pending the Merger	<u>151</u>
Irrinition Fees and Expenses153Representations and Warranties154Iermination of Prior Merger Agreement155Amendments156vOTING AND OTHER ANCILLARY AGREEMENTS157INI Voting Agreements157SioSante Voting Agreements157SioSante Voting Agreements157SioSante Voting Agreements158Contrade Agreements159SioSante Voting Agreements159SioSante Voting Agreements159SioSante Voting Agreements159SioSante Voting Agreement159SioSante Voting Agreement159Jaterial Terms of the CVRs159Discretion of BioSante to Issue CVRs160Material Terms of the CVRs161Sies and Marketing171Reserch and Marketing171Reserch and Proprietary Rights164Description of BioSante's Female Sexual Health. Menopause, Contraception and Male Hypogonadism Products164Sies and Marketing171Siens and Proprietary Rights171Competitions172Soverniew164Siens and Proprietary Rights171Competitions172Soverniews173Simplovees178Simplovees178Simplovees178Soverniews179Simplovees178Simplovees179Simplovees179Simplovees179Simplovees179Simplovees179 <tr< td=""><td>Other Agreements</td><td><u>152</u></td></tr<>	Other Agreements	<u>152</u>
Sepresentations and Warranties154fermination of Prior Merger Agreement155Nuendments157VOTING AND OTHER ANCILLARY AGREEMENTS157NI Voting Agreements157SioSante Voting Agreements157Joack-Up Agreements157Joack-Up Agreements157Joack-Up Agreements157Joack-Up Agreements159Joantingent Value Rights Agreement159Joantingent Value Rights Agreement159Joantingent Value Rights Agreement159Joack-Up Agreements159Joantingent Value Rights Agreement159Joantingent Value Rights Agreement159Joacterion of BioSante to Issue CVRs160MATERIAL US, FEDERAL INCOME TAX CONSEOUENCES OF THE MERGER161Joack-Ip Agreements161Joack-Ip Agreement161Joack-Ip Agreement161Joack-Ip Agreement161Joack-Ip Agreement161Joack-Ip Agreement161Joack-Ip Agreement161Joack-Ip Agreement161Joack-Ip Agreement161Joack-Ip Agreement161Joack-Ip Agreements161Joack-Ip Agreement161Joack-Ip Agreement161Joack-Ip Agreement161Joack-Ip Agreement161Joack-Ip Agreement171Joack-Ip Agreement171Joack-Ip Agreement171Joack-Ip Agreement171Joack-Ip Agreement172Joack-Ip	Termination	<u>152</u>
Ermination of Prior Merger Agreement 155 Amendments 150 VOTING AND OTHER ANCILLARY AGREEMENTS 157 NI Voting Agreements 157 SioSante Voting Agreements 157 Sock-Up Agreements 158 Contring Experiments 158 Contringent Value Rights Agreement 159 Sock-Up Agreements 159 Sock-Up Agreements 159 Contringent Value Rights Agreement 159 Material Terms of the CVRs 159 Discretion of BioSante to Issue CVRs 159 Material Terms of the CVRs 159 Discretion of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products 164 Description of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products 166 Sales and Marketing 171 Patents, Licenses and Proprietary Rights 171 Coverniend Regulation 172 Simplovees 178 Toperties 179 Simplovees 179 Sinplovees 170 Sinplo	Termination Fees and Expenses	<u>153</u>
Amendments 156 VOTING AND OTHER ANCILLARY AGREEMENTS 157 VOTING AND OTHER ANCILLARY AGREEMENTS 157 ANI Voting Agreements 157 SiloSante Voting Agreements 157 Contringent Value Rights Agreement 159 Contingent Value Rights Agreement 159 Socretion of BioSante to Issue CVRs 159 Contracting 159 Socretion of BioSante to Issue CVRs 164 Verview 164 Socretion of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products 164 Sales and Marketing 171 Verview 151 Coverniemental Regulati	Representations and Warranties	<u>154</u>
VOTING AND OTHER ANCILLARY AGREEMENTS157AN Voting Agreements157SioSante Voting Agreements158Jock-Up Agreements158Contingent Value Rights159Jeneral159Contingent Value Rights Agreement159Joisfarte Voting Agreement159Joisfarte Torms of the CVRs159Discretion of BioSante to Issue CVRs160MATERIAL US, FEDERAL INCOME TAX CONSEQUENCES OF THE MERGER161JOSANTES BUSINESS161Derview164Description of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products166Adarketing171Agardatist Internet Regulation171Agardatist Internet Regulation171Steretion and Product Development171Agardatist Semale Sexual Health, Menopause, Contraception and Male Hypogonadism Products166Derview151Derview151Devering Torm of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products161Distriction of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products161Distriction of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products161Distriction of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products161Derview171171Stanter Stanter Serview171Stanter Stanter Serview171Stanter Stanter Serview171Stanter Serview	Termination of Prior Merger Agreement	<u>155</u>
NI Voting Agreements157SioSante Voting Agreements157.ock-Up Agreements158CONTINGENT VALUE RIGHTS158Contingent Value Rights Agreement159Contingent Value Rights Agreement159Material Terms of the CVRs159Oiscretion of BioSante to Issue CVRs160MATERIAL US, FEDERAL INCOME TAX CONSEQUENCES OF THE MERGER161Drerview161StoSANTE'S BUSINESS164Drerview164Description of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products164Stales and Marketing171Research and Product Development171Matufacturing171Zatents, Licenses and Proprietary Rights171Coverniental Regulation173Zimplovees178Creedings179Vailable Information180BIOSANTE'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF181Business Overview181Business Overview181	Amendments	<u>156</u>
ANI Voting Agreements157GioSante Voting Agreements158CONTINGENT VALUE RIGHTS159Contingent Value Rights Agreement159Contingent Value Rights Agreement159Material Terms of the CVRs160MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE MERGER161SIOSANTE'S BUSINESS164Corrview164Corrview164Sescription of BioSante's Female Sexual Health. Menopause. Contraception and Male Hypogonadism Products166Sales and Marketing171Verview164Correstion171Manufacturing171Vanufacturing171Stesarch and Product Development171Manufacturing171Storestion172Coverniental Regulation173Simplovees178Topperties179Available Information180Storestion Sons Coverview181Storestion Sons Coverview181 <t< td=""><td>VOTING AND OTHER ANCILLARY AGREEMENTS</td><td></td></t<>	VOTING AND OTHER ANCILLARY AGREEMENTS	
BioSante Voting Agreements157cock-Up Agreements158CONTINGENT VALUE RIGHTS159Contingent Value Rights Agreement159Contingent Value Rights Agreement159Material Terms of the CVRs159Discretion of BioSante to Issue CVRs160MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE MERGER161BIOSANTE'S BUSINESS164Overview164Description of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products164Description of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products164Description of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products164Description of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products164Description of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products164Description of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products164Description of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products171Patents, Licenses and Proprietary Rights171Contention172Covernmental Regulation173Simplovees179Patents, Licenses and Proprietary Rights179Coverniets178Coverniets179Available Information180BIOSANTE'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF181 <td< td=""><td></td><td><u>157</u></td></td<>		<u>157</u>
BioSante Voting Agreements157cock-Up Agreements158CONTINGENT VALUE RIGHTS159Contingent Value Rights Agreement159Contingent Value Rights Agreement159Material Terms of the CVRs159Discretion of BioSante to Issue CVRs160MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE MERGER161BIOSANTE'S BUSINESS164Overview164Description of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products164Description of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products164Description of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products164Description of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products164Description of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products164Description of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products164Description of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products171Patents, Licenses and Proprietary Rights171Contention172Covernmental Regulation173Simplovees179Patents, Licenses and Proprietary Rights179Coverniets178Coverniets179Available Information180BIOSANTE'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF181 <td< td=""><td>ANI Voting Agreements</td><td>157</td></td<>	ANI Voting Agreements	157
Lock-Up Agreements158CONTINGENT VALUE RIGHTS159Ceneral159Contingent Value Rights Agreement159Contingent Value Rights Agreement159Discretion of BioSante to Issue CVRs160MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE MERGER161BIOSANTE'S BUSINESS164Derrview164Description of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products166Sales and Marketing171Agents, Licenses and Proprietary Rights171Competition172Overmental Regulation173Simplovees179Valatable Information170BIOSANTE'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF181Business Overview181Business Overview181	BioSante Voting Agreements	
CONTINGENT VALUE RIGHTS 159 General 159 Contingent Value Rights Agreement 159 Material Terms of the CVRs 159 Discretion of BioSante to Issue CVRs 160 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE MERGER 161 BIOSANTE'S BUSINESS 164 Description of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products 166 Sales and Marketing 171 Attential Terms of Product Development 171 Manufacturing 171 Competition 172 Governmental Regulation 173 Simplovees 178 Singlable Information 179 Vailable Information 170 Vailable Information 170 Discretions 179 Discretions 179 Vailable Information 170 Discretions	Lock-Up Agreements	
Seneral159Contingent Value Rights Agreement159Material Terms of the CVRs159Discretion of BioSante to Issue CVRs160MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE MERGER161SIOSANTE'S BUSINESS160Description of BioSante's Female Sexual Health. Menopause. Contraception and Male Hypogonadism Products166Sales and Marketing171Research and Product Development171Patents, Licenses and Proprietary Rights171Competition172Stoperties178'poperties179Vallable Information179Vallable Information179Vallable Information179Vallable Information179Vallable Information179Vallable Information179Vallable Information181Susiness Overview181		
General159Contingent Value Rights Agreement159Material Terms of the CVRs159Discretion of BioSante to Issue CVRs160MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE MERGER161BIOSANTE'S BUSINESS164Secretifion of BioSante's Female Sexual Health. Menopause, Contraception and Male Hypogonadism Products164Overview164Description of BioSante's Female Sexual Health. Menopause, Contraception and Male Hypogonadism Products161Sales and Marketing171Research and Product Development171Manufacturing171Patents, Licenses and Proprietary Rights171Competition172Governmental Regulation173Sinployees179Legal Proceedings179Available Information179BIOSANTE'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF181Business Overview181		159
Contingent Value Rights Agreement159Material Terms of the CVRs159Discretion of BioSante to Issue CVRs160MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE MERGER161BIOSANTE'S BUSINESS164Overview164Description of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products166Sales and Marketing171Research and Product Development171Manufacturing171Patents, Licenses and Proprietary Rights171Conperties172Covernies173Imployees179Available Information170Matable Information170BIOSANTE'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF181Business Overview181Business Overview181	General	
Material Terms of the CVRs 159 Discretion of BioSante to Issue CVRs 160 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE MERGER 161 BIOSANTE'S BUSINESS 164 Overview 164 Description of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products 166 Sales and Marketing 171 Research and Product Development 171 Manufacturing 171 Vatents, Licenses and Proprietary Rights 171 Covernimental Regulation 173 Supployees 179 Available Information 170 Available Information 170 Discretions 181 Business Overview 181		
Discretion of BioSante to Issue CVRs 160 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE MERGER 161 BIOSANTE'S BUSINESS 164 Overview 164 Description of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products 166 Sales and Marketing 171 Research and Product Development 171 Mandraturing 171 Patents, Licenses and Proprietary Rights 171 Conpetition 172 Governmental Regulation 173 Employees 179 e.gal Proceedings 179 Available Information 170 BIOSANTE'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF 181 Business Overview 181		
MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE MERGER 161 BIOSANTE'S BUSINESS 164 Overview 164 Description of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products 166 Sales and Marketing 171 Research and Product Development 171 Manufacturing 171 Patents, Licenses and Proprietary Rights 171 Competition 172 Governmental Regulation 173 Imployees 179 egal Proceedings 179 Available Information 179 BIOSANTE'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF 181 Business Overview 181		
InformationInformationBIOSANTE'S BUSINESSInformationSales and NarketingInformationCoverviewInformationSales and MarketingInformationResearch and Product DevelopmentInformationManufacturingInformationPatents, Licenses and Proprietary RightsInformationConspetitionInformationSuppleyeesInformationPropertiesInformationSuppleyeesInformationSIOSANTE'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OFDERATIONSIstBusiness OverviewIstSustiess OverviewIst		
BIOSANTE'S BUSINESS 164 Overview 164 Description of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products 166 Sales and Marketing 171 Research and Product Development 171 Manufacturing 171 Patents, Licenses and Proprietary Rights 171 Coverniental Regulation 172 Governiental Regulation 173 Employees 179 Available Information 180 BIOSANTE'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF 181 Business Overview 181		161
Derview164Description of BioSante's Female Sexual Health. Menopause. Contraception and Male Hypogonadism Products166Sales and Marketing171Research and Product Development171Manufacturing171Patents, Licenses and Proprietary Rights171Competition172Governmental Regulation173Employees178Properties179Legal Proceedings179Available Information180BIOSANTE'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OFDPERATIONS181Business Overview181	BIOSANTE'S BUSINESS	
Derview164Description of BioSante's Female Sexual Health. Menopause. Contraception and Male Hypogonadism Products166Sales and Marketing171Research and Product Development171Manufacturing171Patents, Licenses and Proprietary Rights171Competition172Governmental Regulation173Employees178Properties179Legal Proceedings179Available Information180BIOSANTE'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OFDPERATIONS181Business Overview181		164
Description of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products166Sales and Marketing171Research and Product Development171Manufacturing171Patents, Licenses and Proprietary Rights171Competition172Governmental Regulation173Employees178Properties179Legal Proceedings179Available Information180BIOSANTE'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OFDPERATIONS181Business Overview181	Overview	
Sales and Marketing171Research and Product Development171Manufacturing171Patents, Licenses and Proprietary Rights171Competition172Covernmental Regulation173Employees178Properties179Legal Proceedings179Available Information180BIOSANTE'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF181Business Overview181	Description of BioSante's Female Sexual Health, Menopause, Contraception and Male Hypogonadism Products	
Research and Product Development171Manufacturing171Patents, Licenses and Proprietary Rights171Competition172Covernmental Regulation173Employees178Properties179Legal Proceedings179Available Information180BIOSANTE'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF181Business Overview181	Sales and Marketing	
Manufacturing171Patents, Licenses and Proprietary Rights171Competition172Covernmental Regulation173Employees178Properties179Legal Proceedings179Available Information180BIOSANTE'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF181Business Overview181		
Patents, Licenses and Proprietary Rights171Competition172Convertion173Governmental Regulation173Employees178Properties179Legal Proceedings179Available Information180BIOSANTE'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF181Business Overview181	Manufacturing	
Competition172Governmental Regulation173Employees178Properties179Legal Proceedings179Available Information180BIOSANTE'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OFDPERATIONS181Business Overview181	Patents, Licenses and Proprietary Rights	
Governmental Regulation173Employees178Properties179Legal Proceedings179Available Information180BIOSANTE'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OFDPERATIONS181Business Overview181	Competition	
Employees178Properties179Legal Proceedings179Available Information180BIOSANTE'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OFDPERATIONS181Business Overview181	Governmental Regulation	
Properties 179 Legal Proceedings 179 Available Information 180 BIOSANTE'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF 181 DPERATIONS 181 Business Overview 181	Employees	
Legal Proceedings 179 Available Information 180 BIOSANTE'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF 181 DPERATIONS 181 Business Overview 181	Properties	
Available Information 180 BIOSANTE'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF 181 OPERATIONS 181 Business Overview 181	Legal Proceedings	
BIOSANTE'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF 181 Business Overview	Available Information	
DPERATIONS 181 Business Overview 181	BIOSANTE'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF	
Business Overview 181	OPERATIONS	181
	Business Overview	
	Proposed Merger with ANI	181
	Financial Overview	
	Summary of 2012 Financial Results and Outlook for 2013	
	Critical Accounting Policies and Estimates	
	Results of Operations	
	Liquidity and Capital Resources	
	Recently Issued Accounting Pronouncements	
iii		

Quantitative and Qualitative Disclosures About Market Risk	Page <u>196</u>
BIOSANTE'S MANAGEMENT AND CORPORATE GOVERNANCE	197
Directors	$\frac{197}{197}$
Executive Officers	$\frac{197}{201}$
Corporate Governance Guidelines	201
Director Independence	202
Board Leadership Structure	<u>202</u>
Executive Sessions	<u>203</u>
Board Meetings and Attendance	<u>203</u>
Board Committees	<u>203</u>
Director Nominations Process	<u>206</u>
Board Oversight of Risk	<u>208</u>
Code of Conduct and Ethics	<u>209</u>
Policy Regarding Director Attendance at Annual Meetings of Stockholders	<u>209</u>
Complaint Procedures	<u>209</u>
Process Regarding Stockholder Communications with Board of Directors	<u>209</u>
Section 16(a) Beneficial Ownership Reporting Compliance	<u>210</u>